Speaker Profile
M.D.,Ph.D., Professor, Laboratory Medicine and Infectious Diseases, UCSF
Biography
Charles Chiu, M.D. Ph.D. is a Professor at UCSF, Director of the UCS-FAbbott Viral Diagnostics and Discovery Center (VDDC), and Associate Director of the UCSF Clinical Microbiology Laboratory. Chiu currently leads a translational research laboratory focused on clinical metagenomic sequencing assay development for infectious diseases and genomic investigation and surveillance of emerging pathogens, including the SARSCoV2 coronavirus. He also uses RNASeq transcriptome profiling to develop predictive models using machine learning for host response based diagnosis of COVID19 and other infections. Chius work is supported by funding from the National Institutes of Health (NIH), Department of Defense, US Centers for Disease Control and Prevention (CDC), philanthropy, and the California Initiative to Advance Precision Medicine. He has authored more than 100 peer reviewed publications (20 on COVID19), holds over 15 patents and patent applications, and serves on the scientific advisory board for Mammoth Biosciences, Danaher Dx, Biomesense, and Flightpath.
Session Abstract – PMWC 2026 Silicon Valley
Track Chair:
Victor Velculescu, Johns Hopkins
PMWC Award Ceremony
• Klaus Pantel, UKE & ELBS
• Daniel De Carvalho, University of Toronto
Keynote
• Klaus Pantel, UKE & ELBS
From Mutation to Methylation: The Next Wave of Liquid Biopsy Biomarkers
• Chair: Victor Velculescu, Johns Hopkins
• Daniel De Carvalho, University of Toronto
• Manel Esteller, Sant Pau Research Institute
Advancing Minimal Residual Disease (MRD) Detection through cfDNA and cfRNA Profiling
• Chair: Luis Diaz, MSKCC
• Anne-Renee Hartman, Adela
• Klaus Pantel, UKE & ELBS
AI-Informed Biomarker Trials: Turning Early Detection Signals into Clinically Actionable Designs
• Chair: Manish Kohli, University of Utah
• Luis Diaz, MSKCC
• Amoolya Singh, DELFI Diagnostics
• Peter Bach, DELFI Diagnostics
Fragmentomics for Early Detection: End Motifs and Library Prep
• Varsha Rao, Claret Bioscience
Integrating Genetic Risk with Early Detection: A Precision Prevention Framework for Cardiovascular Disease
• Giordano Botta, Allelica
Role of AI in Liquid Biopsies and Cancer Detection
• Chair: Amoolya Singh, DELFI Diagnostics
• Matthew Baker, Dxcover
